OBJECTIVE: To determine the impact of maternal and fetal single nucleotide polymorphisms in key betamethasone pathways on neonatal outcomes. STUDY DESIGN: DNA was obtained from women given betamethasone and their infants. Samples were genotyped for 73 exploratory drug metabolism and glucocorticoid pathway single nucleotide polymorphisms. Clinical variables and neonatal outcomes were obtained. Logistic regression analysis using relevant clinical variables and genotypes to model for associations with neonatal respiratory distress syndrome was performed. RESULTS: One hundred nine women delivering 117 infants were analyzed. Sixty-four infants (49%) developed respiratory distress syndrome. Multivariable analysis revealed that respiratory distress syndrome was associated with maternal single nucleotide polymorphisms in CYP3A5 (odds ratio [OR], 1.63; 95% confidence interval [CI], 1.16-2.30) and the glucocorticoid resistance (OR, 0.28; 95% CI, 0.08-0.95) and fetal single nucleotide polymorphisms in ADCY9 (OR, 0.17; 95% CI, 0.03-0.80) and CYP3A7*1E (rs28451617; OR, 23.68; 95% CI, 1.33-420.6). CONCLUSION: Maternal and fetal genotypes are independently associated with neonatal respiratory distress syndrome after treatment with betamethasone for preterm labor.
OBJECTIVE: To determine the impact of maternal and fetal single nucleotide polymorphisms in key betamethasone pathways on neonatal outcomes. STUDY DESIGN: DNA was obtained from women given betamethasone and their infants. Samples were genotyped for 73 exploratory drug metabolism and glucocorticoid pathway single nucleotide polymorphisms. Clinical variables and neonatal outcomes were obtained. Logistic regression analysis using relevant clinical variables and genotypes to model for associations with neonatal respiratory distress syndrome was performed. RESULTS: One hundred nine women delivering 117 infants were analyzed. Sixty-four infants (49%) developed respiratory distress syndrome. Multivariable analysis revealed that respiratory distress syndrome was associated with maternal single nucleotide polymorphisms in CYP3A5 (odds ratio [OR], 1.63; 95% confidence interval [CI], 1.16-2.30) and the glucocorticoid resistance (OR, 0.28; 95% CI, 0.08-0.95) and fetal single nucleotide polymorphisms in ADCY9 (OR, 0.17; 95% CI, 0.03-0.80) and CYP3A7*1E (rs28451617; OR, 23.68; 95% CI, 1.33-420.6). CONCLUSION: Maternal and fetal genotypes are independently associated with neonatal respiratory distress syndrome after treatment with betamethasone for preterm labor.
Authors: Barbara J Stoll; Nellie I Hansen; Edward F Bell; Seetha Shankaran; Abbot R Laptook; Michele C Walsh; Ellen C Hale; Nancy S Newman; Kurt Schibler; Waldemar A Carlo; Kathleen A Kennedy; Brenda B Poindexter; Neil N Finer; Richard A Ehrenkranz; Shahnaz Duara; Pablo J Sánchez; T Michael O'Shea; Ronald N Goldberg; Krisa P Van Meurs; Roger G Faix; Dale L Phelps; Ivan D Frantz; Kristi L Watterberg; Shampa Saha; Abhik Das; Rosemary D Higgins Journal: Pediatrics Date: 2010-08-23 Impact factor: 7.124
Authors: S A Scott; K Sangkuhl; E E Gardner; C M Stein; J-S Hulot; J A Johnson; D M Roden; T E Klein; A R Shuldiner Journal: Clin Pharmacol Ther Date: 2011-06-29 Impact factor: 6.875
Authors: J Steven Leeder; Roger Gaedigk; Kenda A Marcucci; Andrea Gaedigk; Carrie A Vyhlidal; Bradley P Schindel; Robin E Pearce Journal: J Pharmacol Exp Ther Date: 2005-04-21 Impact factor: 4.030
Authors: Pauline Smit; Ron H N van Schaik; Marloes van der Werf; Annewieke W van den Beld; Jan W Koper; Jan Lindemans; Huibert A P Pols; Albert O Brinkmann; Frank H de Jong; Steven W J Lamberts Journal: J Clin Endocrinol Metab Date: 2005-06-28 Impact factor: 5.958
Authors: Gregory A Hawkins; Ross Lazarus; Richard S Smith; Kelan G Tantisira; Deborah A Meyers; Stephen P Peters; Scott T Weiss; Eugene R Bleecker Journal: J Allergy Clin Immunol Date: 2009-02-28 Impact factor: 10.793
Authors: M F Hebert; T R Easterling; B Kirby; D B Carr; M L Buchanan; T Rutherford; K E Thummel; D P Fishbein; J D Unadkat Journal: Clin Pharmacol Ther Date: 2008-02-20 Impact factor: 6.903
Authors: M F Hebert; X Ma; S B Naraharisetti; K M Krudys; J G Umans; G D V Hankins; S N Caritis; M Miodovnik; D R Mattison; J D Unadkat; E J Kelly; D Blough; C Cobelli; M S Ahmed; W R Snodgrass; D B Carr; T R Easterling; P Vicini Journal: Clin Pharmacol Ther Date: 2009-03-18 Impact factor: 6.903
Authors: David M Haas; Jessica Dantzer; Amalia S Lehmann; Santosh Philips; Todd C Skaar; Catherine L McCormick; Scott J Hebbring; Jeesun Jung; Lang Li Journal: Am J Obstet Gynecol Date: 2013-01-04 Impact factor: 8.661
Authors: Todd D Nebesio; Jamie L Renbarger; Zeina M Nabhan; Sydney E Ross; James E Slaven; Lang Li; Emily C Walvoord; Erica A Eugster Journal: Int J Pediatr Endocrinol Date: 2016-09-26
Authors: Aizati N A Daud; Jorieke E H Bergman; Wilhelmina S Kerstjens-Frederikse; Henk Groen; Bob Wilffert Journal: Int J Mol Sci Date: 2016-08-13 Impact factor: 5.923